Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Liabilities and Shareholders Equity (2021 - 2026)

Zentalis Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $253.1 million for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity fell 34.1% year-over-year to $253.1 million; the TTM value through Mar 2026 reached $1.2 billion, down 30.5%, while the annual FY2025 figure was $289.0 million, 32.85% down from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $253.1 million at Zentalis Pharmaceuticals, down from $289.0 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $621.4 million in Q2 2023 and troughed at $253.1 million in Q1 2026.
  • A 5-year average of $460.3 million and a median of $489.3 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: rose 20.62% in 2023 and later plummeted 34.1% in 2026.
  • Year by year, Liabilities and Shareholders Equity stood at $539.3 million in 2022, then grew by 2.3% to $551.7 million in 2023, then dropped by 22.0% to $430.3 million in 2024, then crashed by 32.85% to $289.0 million in 2025, then dropped by 12.42% to $253.1 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for ZNTL at $253.1 million in Q1 2026, $289.0 million in Q4 2025, and $327.2 million in Q3 2025.